Australia-wide dispatch

Quantified
Peptides
CBL-514 20mg — research peptide, lyophilised powder in a glass vial, supplied by Quantified Peptides, Sydney, Australia. For in-vitro research use only.

Peptides

CBL-514

CBL-514, an investigational small-molecule compound studied in adipocyte research. Supplied as a lyophilised powder in 20mg vials.

Supplied as lyophilised powder in a 20mg specification. Storage: -20°C · Keep dry, avoid light. Dispatched from Sydney, Australia-wide.

Product information

About CBL-514

Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.

CBL-514 is an investigational small-molecule compound developed by Caliway Biopharmaceuticals. Unlike most of this catalogue it is not a peptide.

It has been studied for its ability to induce apoptosis in adipocytes. Preclinical reports describe changes in caspase-3 and the Bax to Bcl-2 ratio, and the compound has since been taken into Phase 2 clinical trials that measure localised subcutaneous fat. One of those trials has been published in a peer-reviewed journal; other results are available only as company announcements.

CBL-514 is not an approved medicine. It is supplied here as a reference material for in-vitro research into adipocyte biology.

Type
Small-molecule compound (not a peptide)
Research Areas
Adipocyte apoptosis, subcutaneous adipose tissue
Developer
Caliway Biopharmaceuticals
Primary Research
Adipocyte apoptosis
Key Markers
Caspase-3, Bax/Bcl-2 ratio
Development Stage
Phase 2 completed (investigational)
Regulatory Status
Not approved
  1. 01Adipocyte ApoptosisPreclinical work reported by the developer describes dose-dependent apoptosis of adipocytes in vitro and in vivo following exposure to CBL-514.
  2. 02Apoptosis MediatorsThe same preclinical studies report an increase in caspase-3 and in the Bax to Bcl-2 ratio in adipocytes, the markers used to characterise the apoptotic response.
  3. 03Clinical InvestigationCBL-514 has been studied in placebo-controlled Phase 2 trials measuring subcutaneous fat volume. It is investigational and has not been approved by any regulator.

References

  1. 1Randomized, placebo-controlled Phase 2 study of CBL-514 for reduction of abdominal subcutaneous fat. Aesthet Surg J. 2025. PMC12080885.
  2. 2ClinicalTrials.gov: clinicaltrials.gov/search?intr=CBL-514
  3. 3PubMed: pubmed.ncbi.nlm.nih.gov/?term=CBL-514

Also in this range.

Compounds the supplier files alongside this one.

View the range